Quick answer
How can a lab check the quality of an IGF-1 LR3 lot it has received? Run a short acceptance workflow: reconcile the label and lot number against the certificate of analysis where one is published, inspect the powder, check solubility and clarity after reconstitution, confirm concentration with an orthogonal method, look at the protein by non-reduced and reduced SDS-PAGE, consider endotoxin if the stock goes into sensitive cells, and run a functional readout such as Akt phosphorylation in a reporter cell line against a reference lot. Keep every result with the lot number. Analytical purity and identity answer whether the right molecule is present; only a bioassay shows whether it still works.
Most quality-control guidance for peptides focuses on what the certificate of analysis says. For a protein-sized, disulfide-bonded reagent like IGF-1 LR3, the certificate is where verification starts, not where it ends. This guide sets out an incoming-inspection workflow a research group can run itself, from the receiving record to a functional bioassay, and explains what each step can and cannot detect. For the analytical-method side (RP-HPLC, SEC, mass analysis) see the companion IGF-1 LR3 purity testing guide; this article concerns the lab's own acceptance checks. For laboratory research use only; not for human consumption.
What the vial is, and what a certificate can show
The IGF-1 LR3 product page lists a 1 mg lyophilized powder in a sealed clear glass vial, purity stated as 98% or higher by HPLC, molecular formula C400H625N111O115S9, and storage at 2–8 °C with −20 °C for long-term holding. Sequence and identity are reported on the certificate of analysis where one is published. A published certificate typically carries measured HPLC purity, identity confirmation, lot number and test date; see how to read a COA. What a certificate cannot show is how the vial behaved afterwards: transit temperature, handling, moisture ingress or aggregation after dissolution. Acceptance testing exists to cover that gap.
| Check | Question it answers | Cannot tell you |
|---|---|---|
| Label and lot reconciliation | Does the vial match the document? | Whether the content is correct |
| Visual inspection | Is the solid normal in appearance? | Purity or folding |
| Solubility and clarity | Does it dissolve without haze or particles? | Whether soluble aggregates are present |
| Concentration (A280 or BCA) | Is the protein quantity in the expected range? | Identity; activity |
| SDS-PAGE (reduced and non-reduced) | Is there one dominant band, and is there covalent aggregate or fragmentation? | Misfolding with the same mass |
| Endotoxin assay | Is endotoxin below the limit the cells tolerate? | Protein quality |
| Functional bioassay | Does it signal like a reference lot? | Which impurity is responsible if not |
Step 1: reconcile the paperwork
Before opening, match the lot number and compound name on the vial to the receiving record, then to the entry in the COA library where one is published. Note the date, storage condition on arrival and any transit anomaly. If no certificate is yet listed for the lot, record that explicitly. The third-party testing explainer describes why an independent laboratory's result adds information beyond a supplier's own.
Step 2: inspect the powder and the solution
Freeze-dried protein is normally a white to off-white cake or loose solid; a cake displaced onto the wall during transit is cosmetic (see what is normal in a vial). After reconstitution, the solution should be clear and colorless without particles. Haze, strands or foam that persists are reasons to stop and record; the cloudy-vial guide lists likely causes. Protein solutions can be inspected against a dark and a light background, and a drop on a microscope slide can reveal particles invisible to the eye.
Step 3: confirm concentration independently
The vial's nominal mass is a starting point, not a measurement: the powder also carries counterions and residual water, so net protein content is below gross mass. For a protein with aromatic residues, absorbance at 280 nm gives a quick estimate when the extinction coefficient is known from the sequence; a colorimetric assay such as BCA gives an independent figure, with the caveat that it is calibrated against a standard protein and can differ in response. Compare the two and record both. If they disagree widely, work from the measured figure and note which method was used. Dilution arithmetic itself follows the formula in the volume calculation guide and the calculator.
Step 4: look at the protein on a gel
SDS-PAGE separates by size, so a dominant band near the expected mass of about 9 kDa supports identity at a coarse level, and extra bands suggest fragments or covalent oligomers. Running reduced and non-reduced lanes side by side is informative for a disulfide-bonded protein: non-reduced mobility is sensitive to disulfide pairing, and a smear or ladder that collapses on reduction points to disulfide-linked species. A gel is semi-quantitative and does not see non-covalent aggregates or same-mass misfolded isoforms, which is why chromatographic and functional checks are complementary (Mahler et al., 2009; Mant et al., 2007).
Step 5: endotoxin for sensitive cells
Endotoxin from Gram-negative bacteria activates innate-immune signaling at very low levels and can confound experiments in immune, endothelial and primary cells (Gorbet and Sefton, 2005). A growth-factor stock used at low final concentration contributes little endotoxin after dilution, but the contribution scales with stock use, so a limulus-based assay is worth running on a stock if the downstream cells are sensitive. Record the result with the assay's detection limit; a value below detection is not the same as zero.
Step 6: a functional bioassay
Analytical methods tell you what molecule is present; a bioassay tells you whether it does the job. A simple functional check uses a cell line that expresses IGF-1 receptor and reads phospho-Akt or phospho-ERK after a short stimulation, as described in the receptor-signaling literature. Run a dose series on the new lot beside a retained reference lot or a recombinant IGF-1 reference, fit curves and compare EC50 values and maximal response. Acceptance limits should be set in advance, for example that the new lot's EC50 falls within a pre-declared fold of the reference. Proliferation assays give an alternative with longer duration and higher variability.
Example acceptance criteria
Criteria should be written before the first lot is tested and tuned to what the experiments need. The values below are placeholders showing the structure of an acceptance sheet, not recommended limits.
| Parameter | Method | Example criterion structure | Action if outside |
|---|---|---|---|
| Appearance | Visual | Solid intact, no discoloration | Record; photograph; query if abnormal |
| Solution clarity | Visual against dark and light background | Clear, no particles after gentle reconstitution | Stop; repeat with fresh vial; see cloudy-vial causes |
| Concentration | A280 and BCA | Two methods agree within a pre-set percentage | Use measured value; note method |
| Banding | Non-reduced and reduced SDS-PAGE | One dominant band near expected mass; no new bands vs. reference lot | Run chromatography; hold lot |
| Endotoxin | Limulus-based assay | Below the limit tolerated by the cell type | Do not use in sensitive cells |
| Activity | Phospho-Akt or proliferation dose series | EC50 within a pre-declared fold of the reference lot | Quarantine; repeat; contact supplier with data |
Writing the criteria down first also protects against a common bias: tightening or loosening limits after seeing a result that is inconvenient.
Step 7: lot-to-lot records
Keep a one-page log per lot: arrival condition, certificate status, solubility result, concentration by two methods, gel image, endotoxin value if measured, bioassay curve, stock preparation date, aliquot count and freezer location. When an experiment behaves unexpectedly, this log lets you separate a reagent problem from a biology problem. Retaining a small frozen aliquot of every lot that was used in a reported experiment makes later comparisons possible. The reproducibility literature argues that unrecognized variation in reagents is a significant contributor to results that cannot be repeated (Freedman et al., 2015), and a lot log is the cheapest defense against it.
When a lot fails a check
Define in advance what constitutes failure and what is done: quarantine the vial, repeat the check with fresh material to exclude a handling error, run an orthogonal method, and contact the supplier with data attached. Avoid changing several variables at once. A failed bioassay with passing analytics suggests folding or handling; a failed concentration check with a passing bioassay suggests a quantitation or salt-content issue. Wider guidance on supplier selection and documentation lives in vetting a research peptide supplier.
Related reading
- IGF-1 LR3 product page
- IGF-1 LR3 research overview
- IGF-1 LR3 purity testing
- How to read a COA
- Third-party testing explained
- Understanding HPLC purity
- Reconstitution calculator
- COA library
Frequently asked questions
What is the first thing to check on receiving IGF-1 LR3?
Match the compound name and lot number on the vial to the receiving record and to the certificate of analysis where one is published, and note arrival condition and any transit problem.
Why is a purity percentage not enough for IGF-1 LR3?
It is a disulfide-bonded, protein-sized molecule. HPLC purity describes chromatographic composition, but misfolded isoforms with the same mass or non-covalent aggregates may need other methods.
Can I trust the vial mass as my protein quantity?
Regard it as nominal. Counterions and residual water mean net protein is lower than gross mass, so confirm by A280 or BCA when concentration matters.
What does a non-reduced SDS-PAGE lane add?
It is sensitive to disulfide pairing and covalent oligomers. Comparing it with the reduced lane can show disulfide-linked species that disappear on reduction.
Do I need an endotoxin test?
It is worthwhile if the stock goes into immune, endothelial or primary cells. Record the assay's detection limit, because a result below it is not zero.
What is the simplest functional test?
Stimulate an IGF-1R-expressing cell line for a short period and read phospho-Akt or phospho-ERK across a dose series, comparing the new lot with a retained reference lot.
How should acceptance limits be set?
Before testing, for example a fold-range for EC50 relative to the reference lot and a minimum maximal response, so the decision is not made after seeing the data.
What if the analytics pass but the bioassay fails?
Suspect folding, aggregation or handling. Repeat with fresh material, run an orthogonal method and check how the stock was prepared and stored.
What information belongs in a lot log?
Arrival condition, certificate status, solubility, concentration by two methods, gel image, endotoxin, bioassay curve, preparation date, aliquots and storage location.
Where can I find a certificate for this product?
Certificates are listed in the COA library where they have been published; check the lot number in hand against the listing.
Related reading: How to Reconstitute IGF-1 LR3: A Lab Handling Guide, IGF-1 LR3 Complete Guide: Where the Research Fits, IGF-1 LR3 Storage & Stability: Degradation Routes.
References
- Mahler HC, Friess W, Grauschopf U, Kiese S. Protein aggregation: pathways, induction factors and analysis. J Pharm Sci. 2009;98(9):2909-2934. doi:10.1002/jps.21566
- Mant CT, Chen Y, Yan Z, et al. HPLC analysis and purification of peptides. Methods Mol Biol. 2007;386:3-55. doi:10.1007/978-1-59745-430-8_1
- Gorbet MB, Sefton MV. Endotoxin: the uninvited guest. Biomaterials. 2005;26(34):6811-6817. doi:10.1016/j.biomaterials.2005.04.063
- Hakuno F, Takahashi SI. 40 years of IGF1: IGF1 receptor signaling pathways. J Mol Endocrinol. 2018;61(1):T69-T86. doi:10.1530/jme-17-0311
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. doi:10.1007/s11095-009-0045-6
- Freedman LP, Cockburn IM, Simcoe TS. The economics of reproducibility in preclinical research. PLoS Biol. 2015;13(6):e1002165. doi:10.1371/journal.pbio.1002165
- Bayne ML, Applebaum J, Chicchi GG, et al. Structural analogs of human insulin-like growth factor I with reduced affinity for serum binding proteins and the type 2 IGF receptor. J Biol Chem. 1988;263(13):6233-6239. doi:10.1016/s0021-9258(18)68777-0
